Recently, we have also shown that vorinostat is able to increase the therapeutic efficacy of EGFR-TKIs gefitinib or erlotinib in a panel of NSCLC cell lines by altering redox homeostasis [20]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.